VYVGART Education Line (argenx and Snow Companies)
VYVGART (efgartigimod alfa-fcab) is a recently FDA-approved treatment for adults with anti-AChR antibody positive generalized myasthenia gravis (gMG). In order to optimally support patients’ treatment journeys, argenx needed to provide a way to meet patients where they are and deliver educational information about the brand.
argenx and Snow established a toll-free call line for patients, caregivers, and healthcare providers with gMG-related questions. Educators often connected callers with resources and service areas, such as My VYVGART Path, argenx’ Patient Support Program with dedicated Nurse Case Managers.
The team trained the call center staff about MG disease state and VYVGART product information. All educators were supplied with a script and FAQ document to guide the conversation. A supplemental texting program and fulfillment service ensured effective follow-up.
January through May 2022, the VYVGART Education Line served 881 callers and 91% expressed a commitment to follow educator’s advice. This high motivational impact shows that offering patients customized, white-glove services make a tremendous difference in shaping treatment journeys.
